Oral Niacinamide for Skin Cancer Prevention: Large VA Study Reinforces Evidence
A large US Department of Veterans Affairs (VA) study confirms that oral niacinamide (nicotinamide, vitamin B3) reduces new non-melanoma skin cancer (basal cell carcinoma + squamous cell carcinoma) risk. It reinforces the 2015 NEJM ONTRAC trial with real-world large-scale data.
ONTRAC trial as the starting point
The 2015 ONTRAC (Oral Nicotinamide to Reduce Actinic Cancers) trial in NEJM is the starting point. 386 patients with prior non-melanoma skin cancer were given nicotinamide 500 mg twice daily (1 g/day) or placebo for 12 months.
Core results.
23% reduction in new non-melanoma skin cancer rate (P=0.02). Reduction in both BCC and SCC.
13% reduction in actinic keratosis incidence.
Side effects: No difference vs placebo. Good safety.
This data established niacinamide as the first validated non-prescription drug for skin cancer chemoprevention.
VA large-scale real-world data
The VA study tested ONTRAC’s results at larger scale, longer follow-up, in real-world conditions. A cohort analysis in veterans with prior non-melanoma skin cancer or high risk.
Core results (announced September 2025).
Niacinamide oral users showed meaningful reduction in new skin cancer risk.
Effect size consistent with ONTRAC: roughly 20-30% reduction range.
Largest benefit populations: those with multiple prior skin cancers, those with abundant actinic keratoses, immunosuppressed populations (post-transplant patients, those on autoimmune treatment).
The significance: ONTRAC’s effect reproduces in real-world conditions. Effects hold outside controlled trial settings.
Mechanism: not simple vitamin replacement
Niacinamide’s skin cancer prevention works at multiple levels.
ATP recovery. UV exposure depletes cellular ATP (energy). Without ATP, DNA repair efficiency drops. Niacinamide is a precursor for NAD+ biosynthesis, supporting ATP production. Cells maintain energy for damage repair after UV exposure.
DNA repair enhancement. NAD+ is a cofactor for DNA repair enzymes (PARP, sirtuins). UV-induced DNA mutations are repaired more efficiently.
Immune recovery. UV temporarily suppresses skin immunity (Langerhans cell function decline). Niacinamide weakens this suppression, keeping immune surveillance (abnormal cell removal) operational.
Anti-inflammation. Partially inhibits NF-κB and other inflammatory pathways. Blocks chronic inflammation pathways contributing to tumor formation.
This is pharmacological effect, not simple vitamin deficiency replacement. The 1 g/day dose isn’t reachable through normal dietary intake.
Difference from topical niacinamide
In skin care products, niacinamide (typically at 4-10%) has different effects.
Reduced redness and pigmentation. Multiple clinical trials.
Sebum control. Improved pore appearance.
Strengthened skin barrier. Stimulates ceramide synthesis.
Reduced fine lines. Some collagen synthesis stimulation.
These topical effects act at the dermal surface. Skin cancer chemoprevention requires oral systemic distribution. Two distinct mechanisms.
Who’s a good candidate
General guidance from ONTRAC and VA data combined.
Prior skin cancer patients: Diagnosed or treated for non-melanoma skin cancer. Consider oral niacinamide 1 g/day after physician discussion.
Multiple actinic keratoses: Population with many photodamage-related lesions. Adjunct chemoprevention.
Immunosuppressed patients: Post-organ-transplant, those on autoimmune treatment have 5-10x general skin cancer risk. Strong indication for chemoprevention.
High UV occupations/environments: Outdoor workers, fishermen, farmers. Additional protection on top of UV shielding.
General population: UV protection (SPF 30+, hats, clothing) is first strategy. Strong family history of skin cancer with prominent photoaging warrants physician consultation.
Dose and side effects
Dose: 500 mg twice daily (1 g/day) is the ONTRAC-validated dose. Take with meals in divided doses to reduce GI side effects.
Side effects: Generally mild. GI discomfort is most common at 1 g/day. Liver enzyme elevation reported at high doses (above 3 g/day), so self-prescribing above the clinical dose is risky.
Effect persistence after stopping? Effects tend to decline after discontinuation. Continuous use is recommended.
Combinations with other vitamins/minerals
Additional nutrients supporting niacinamide’s skin cancer prevention.
Vitamin D: Deficiency signals increased skin cancer risk. Adequate 25(OH)D (50-70 nmol/L) recommended.
Selenium: Cofactor for antioxidant glutathione peroxidase. Diet typically suffices (1-2 Brazil nuts/day).
Carotenoids (lutein, zeaxanthin, beta-carotene): UV antioxidant support. Diet (colorful vegetables) prioritized.
Sun protection SPF 30+ remains the foundation. Niacinamide is adjunctive.
Connection to this quarter’s data
Combined with other aging mechanism data this quarter, the picture sharpens.
Mitochondria (Lancôme x Timeline Urolithin A): Mitophagy as cellular aging recovery target.
Senescent cells (Mayo Clinic D+Q): Reducing senescent cell burden recovers bone formation.
Neuromuscular (K2 TAKEOVER): Gas6 carboxylation recovers neuromuscular function.
Skin cancer prevention (niacinamide): NAD+-dependent DNA repair recovers UV damage.
All are different layers of NAD+, mitochondria, autophagy, and senescent cell clearance — molecular aging mechanisms. Niacinamide is the most-studied NAD+ precursor.
Daily guide
Skin cancer prevention is a multi-layer matrix.
Layer 1: UV protection. The most powerful primary prevention. SPF 30+, PA+++, hats, UV-protective clothing, limited midday sun exposure.
Layer 2: Regular skin checks. Annually, or every 6 months for high-risk groups, with a dermatologist. Check for new and changing moles (ABCDE rule).
Layer 3: Nutritional foundation. Adequate vitamin D, dietary carotenoids, omega-3, sufficient protein.
Layer 4: Chemoprevention. Oral niacinamide 1 g/day for prior cancer or high-risk populations. Discuss with a physician.
Layer 5: Photoaging topical care. Retinoids (evening), vitamin C (morning), peptides. Topical effects on photoaging scars are separate mechanisms.